Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials

Pain Practice

Volumn 15, Issue 6, 2015, Pages 564-571

  Nalamachu, Srinivas R ^a   Pergolizzi, Joseph ^b,c,d   Taylor, Robert ^e   Slatkin, Neal E ^f   Barrett, Andrew C ^g   Yu, Jing ^g   Bortey, Enoch ^g   Paterson, Craig ^g   Forbes, William P ^g  

^a Clinical Research   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Association of Chronic Pain Patients   (United States)

^e NEMA Research Inc   (United States)

^f Palliative Care Center Silicon Valley and Hospice of the Valley   (United States)

^g Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

Methylnaltrexone; Opioid induced constipation; Opioids; opioid receptor

Indexed keywords

17 METHYLNALTREXONE; OPIATE; PLACEBO; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; QUATERNARY AMMONIUM DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADVANCED CANCER; AGED; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER GROWTH; COMPARATIVE EFFECTIVENESS; CONFUSION; CONSTIPATION; DIARRHEA; DIGESTIVE TRACT PARAMETERS; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FALLING; FEMALE; FLATULENCE; HUMAN; HYPERHIDROSIS; INCIDENCE; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESCUE MEDICATION FREE BOWEL MOVEMENT; RESTLESSNESS; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; ADULT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS, OPIOID; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84935147230     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12218     Document Type: Article

References (21)

1. Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201-211.
2. Clemens KE, Klaschik E. Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide. Ther Clin Risk Manag 2010;6:77-82.
3. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (probe 1). Pain Med. 2009;10:35-42.
4. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008;27:1224-1232.
5. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35:214-228.
6. Candy B, Jones L, Goodman ML, Drake R, Tookman A, Laxatives OR. Methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011;1:Cd003448.
7. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5a Suppl):11s-18s.
8. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 1986;237:945-949.
9. Tavani A, Bianchi G, Ferretti P, Manara L. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci 1980;27:2211-2217.
10. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-144.
11. Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 2007;82:48-53.
12. Russell J, Bass P, Goldberg LI, Schuster CR, Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982;78:255-261.
13. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997;87:765-770.
14. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59:469-475.
15. Relistor (Methylnaltrexone Bromide) Subcutaneous Injection [Package Insert]. Raleigh, NC: Salix Pharmaceuticals Inc.; 2012.
16. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39-46.
17. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-2343.
18. Dahan A. The importance of individual differences in response to opioid therapy. Therapy. 2009;6:633-635.
19. Department Of Veterans Affairs, Department Of Defense, The Management Of Opioid Therapy For Chronic Pain Working Group. A/Dod Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. Washington, DC. U S. Department Of Veterans Affairs, Department Of Defense; May 2010.
20. Yuan CS, Foss JF. Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology 1999;38:425-432.
21. Slatkin NE, Lynn R, Su C, Wang W, Israel RJ. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage 2011;42:754-760.